SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern.
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 03 2023
15 03 2023
Historique:
entrez:
15
3
2023
pubmed:
16
3
2023
medline:
17
3
2023
Statut:
epublish
Résumé
COVID-19 in immunocompromised hosts has emerged as a difficult therapeutic management problem. Immunocompromised hosts mount weak responses to SARS-CoV-2 and manifest infection outcomes ranging from severe disease to persistent infection. Weakened immune systems mean greater viral loads and increased opportunities for viral evolution. Gupta, Konnova, et al. report the emergence of resistant SARS-CoV-2 variants in immunocompromised patients after monoclonal antibody (mAb) therapy. mAbs target only a single determinant in the viral Spike protein, which is a weakness of such therapy when treating a mutagenic and variable virus. Hence, the emergence of mAb resistance could have been anticipated, but its documentation is important because it has major public health implications, since such resistant variants have the potential to spread and escape vaccine immunity. For immunocompromised patients, these findings suggest the need for combination therapy with antiviral drugs and the use of polyclonal antibody preparations such as convalescent plasma.
Identifiants
pubmed: 36919696
pii: 168603
doi: 10.1172/JCI168603
pmc: PMC10014096
doi:
pii:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Antibodies, Neutralizing
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI052733
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL059842
Pays : United States
Références
Ann Oncol. 2021 Nov;32(11):1445-1447
pubmed: 34352377
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Nat Commun. 2022 Oct 29;13(1):6478
pubmed: 36309490
J Gen Virol. 2023 May;104(5):
pubmed: 37167085
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Science. 2021 Dec 3;374(6572):1179
pubmed: 34855502
JAMA Oncol. 2021 Jun 17;:
pubmed: 34137799
J Clin Invest. 2023 Mar 15;133(6):
pubmed: 36727404
Nat Cancer. 2023 Jan;4(1):96-107
pubmed: 36581734
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Virology. 2004 Jan 20;318(2):608-12
pubmed: 14972528
J Virol. 2005 Apr;79(7):3962-8
pubmed: 15767398
JAMA Netw Open. 2023 Jan 3;6(1):e2250647
pubmed: 36633846
JAMA Netw Open. 2022 Aug 1;5(8):e2228997
pubmed: 36036937
J Infect Dis. 2010 Mar 15;201(6):946-55
pubmed: 20144042
PLoS One. 2009 May 22;4(5):e5672
pubmed: 19478856
J Infect Dis. 2011 Mar 1;203(5):674-82
pubmed: 21208913
Pathogens. 2022 Jul 22;11(8):
pubmed: 35894046
Lancet Microbe. 2021 Sep;2(9):e424
pubmed: 34341781
Clin Infect Dis. 2023 Feb 8;76(3):408-415
pubmed: 36189631
Diagn Microbiol Infect Dis. 2022 May;103(1):115656
pubmed: 35231807
J Infect. 2022 Nov;85(5):e162-e163
pubmed: 35878684
PLoS Pathog. 2011 Dec;7(12):e1002390
pubmed: 22144891